[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"moderate-to-severe-vernal-keratoconjunctivitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:moderate-to-severe-vernal-keratoconjunctivitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100605988","phase-2-a-study-to-compare-the-effectiveness-and-safety-of-t1695-versus-ciclosporin-in-participants-with-moderate-to-severe-vernal-keratoconjunctivitis-100605988",false,"NCT07169695","A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis","Efficacy and Safety Assessment of T1695 Ophthalmic Suspension, Versus Ciclosporin Ophthalmic Emulsion, in Participants With Moderate to Severe Vernal Keratoconjunctivitis (VKC)","Main Inclusion Criteria:\n\n* Informed consent signed and dated\n* Male or female participant from 4 years to less than 18 years old.\n* Participant with grading score of 3 or 4 on the Bonini scale for clinical grading of VKC in each eye.\n\nMain Exclusion Criteria:\n\nParticipants must not have any conditions which might exclude them from participating, could interfere with the study, or pose an unacceptable risk to their health.","ALL","4 Years","17 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The aim of the study is to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants with Moderate to Severe Vernal Keratoconjunctivitis",[27],"Moderate to Severe Vernal Keratoconjunctivitis",[29],"Vernal Keratoconjunctivitis","RECRUITING","2026-04-21",{"date":33,"type":34},"2026-04-22","ACTUAL",{"date":36,"type":34},"2026-03-24",{"date":38,"type":21},"2027-01-21",{"name":40,"class":41},"Laboratoires Thea","INDUSTRY",11]